For a world without autoimmune diseases
Therapeutic Vaccines and
Active Targeted Immunotherapies
Who we are
CuraVac is a clinical-stage biotechnology company developing Therapeutic Vaccines and Active Targeted Immunotherapies for autoimmune diseases.
With the use of a new revolutionary technique based on complementary peptides, we aim to induce long-term immunity against autoimmune diseases such as Multiple Sclerosis (MS), Myasthenia Gravis (MG), Type 1 diabetes, Graves’ disease, Systemic Lupus Erythematosus (SLE) and Hashimoto’s disease.
CuraVac’s CV-MG is a potential breakthrough in MG treatments and a potential therapeutic revolution for all autoimmune diseases – being the first to possibly bring a long-lasting improvement and a potential cure to patients.
Autoimmune diseases in the U.S.
The CuraVac team is composed of 3 key people at the center of a collaborative network of the highest quality from the industry and the academic world: Dr. Stéphane Huberty, Professor J. Edwin Blalock and Nicolas Havelange.
Dr. Stéphane Huberty
Founder and Chief Executive Officer.
Professor J. Edwin Blalock
Chief Scientific Officer.Discoverer of the Therapeutic Vaccine technology.
Nicolas Havelange
Chief Operating Officer of CuraVac.
Our Independent Advisory Board is composed of key specialists from the industry and the academic world who provide the management team with valuable input in its strategic decision making.
Dr. Didier Hoch, M.D.
CEO of BIOVISION and the World Life Sciences Forum. He is a medical doctor and has more than 25 years of experience in the pharmaceutical and vaccine industries.
Dr. Jean-Paul Prieels, Ph.D.
Served as a Senior Vice President of Research and Development at GlaxoSmithKline Biologicals (now GSK Vaccines) until January 2011.
Dr. Bruce Forrest, M.D., MBA
Dr. Forrest has over 25 years of global leadership in pharmaceutical development with specialty expertise in vaccines and biopharmaceuticals development.
Prof. Dr. Marc De Baets, M.D., Ph.D.
Prof. Dr. Marc De Baets is experienced in research and clinical management of MG patients. He works at the neurology clinic of Maastricht University Hospital where he sees 15 MG patients each week.
Foundation
CuraVac was founded in 2002 by Dr. Stéphane Huberty, a Belgian medical doctor who suffered from Myasthenia Gravis. Soon after, the company acquired the complementary peptide patent, raised funds and got organized as a management company at the center of a network of collaborations and sub-contracting companies. The original discoverer of the vaccine production technique, Professor J. Edwin Blalock also joined CuraVac as a consultant.
Present day
Following a Clinical Trial Authorization received in November 2015, 24 patients received three injections of the MG therapeutic vaccine in a phase 1B clinical trial that took place at the Antwerp University hospital (UZA) in Belgium. The preliminary results were communicated in May 2017 at the 13th International Conference on Myasthenia Gravis and Related Disorders at the New York Academy of Science.
The final results of phase 1B, communicated in June 2018, demonstrated an excellent safety profile and called for a phase 2 efficacy clinical trial.
CuraVac is presently preparing a phase 2 efficacy clinical trial with a more potent formulation of the MG Therapeutic Vaccine: CV-MG02.
- In 2009, the human formulation of the MG vaccine is manufactured following GLP and GMP guidelines.
The myasthenia gravis Therapeutic Vaccine, our first vaccine, was granted Orphan Drug Designation in Europe by a team of independent experts of the 27 European member states.
- In 2011, the MG therapeutic vaccine was granted Orphan Drug Designation in the USA by the FDA
They didn’t know it was impossible so they did it
— Mark Twain
Wish to ask us about our progress, our platform, share your story or anything else?
You can send us an email at info@curavac.com or simply submit the form here.